DGAP-News: Evotec enters integrated alliance with AstraZeneca in kidney disease

DGAP-News: Evotec enters integrated alliance with AstraZeneca in kidney disease

DGAP-News: Evotec AG / Key word(s): Alliance
Evotec enters integrated alliance with AstraZeneca in kidney disease

21.10.2013 / 07:30


Hamburg, Germany - 21 October 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced that it has signed an
agreement with AstraZeneca in the field of kidney diseases. Initial focus
of the alliance will be exploring compounds and targets with novel
mechanisms that have disease-modifying potential for the treatment of
chronic kidney disease.

Under the terms of this licence and collaboration agreement, AstraZeneca
will receive access to a selected series of molecules identified in a
screening effort, which is part of Evotec's systematic kidney disease
initiative. This particular programme has been designed to explore a key
mechanism in the field of chronic kidney disease. AstraZeneca will provide
industrial scope and scale as well as pharmaceutical development expertise
and marketing capabilities.

The agreement between Evotec and AstraZeneca triggers an undisclosed
upfront payment as well as pre-clinical, clinical and regulatory
milestones. Evotec is also eligible for additional milestone and royalty
payments related to commercialisation. Evotec will receive research funding
for work that will be conducted in collaboration with AstraZeneca. Specific
financial details were not disclosed.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: 'Exploring
novel mechanisms and novel targets in the field of kidney disease is a
logical next step for Evotec. We are very excited about AstraZeneca joining
one of our programmes. AstraZeneca is a great partner sharing not only our
vision but making valuable contributions beyond in an integrated discovery
and development process.'

Dr Marcus Schindler, Head of Cardiovascular and Metabolic Diseases iMed,
AstraZeneca, added: 'Cardiovascular and metabolic diseases (CVMD)
represents one of the three core areas for AstraZeneca. Within CVMD, we are
committing significant efforts on research and development of potential new
treatments for diabetic nephropathy, end-stage as well as chronic kidney
disease. Our goal is to identify and develop effective therapies to halt or
slow down the decline of renal function for patients suffering from kidney
diseases. This new collaboration complements our research efforts in the
renal disease space. Evotec has built a leading drug discovery platform in
the field of kidney diseases and is well-positioned to work with us to
generate highly innovative drug candidates so that we can accelerate the
delivery of new medicines to patients.'

Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: astrazeneca.com.

In cardiovascular and metabolic diseases AstraZeneca focuses the small
molecule research on three strategic areas: Cardiac Regeneration, Islet
Health (diabetes) and Diabetic Nephropathy.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is

Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

End of Corporate News


21.10.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English                                                
Company:     Evotec AG                                              
             Manfred Eigen Campus / Essener Bogen 7                 
             22419 Hamburg                                          
Phone:       +49 (0)40 560 81-0                                     
Fax:         +49 (0)40 560 81-222                                   
E-mail:      info@evotec.com                                        
Internet:    www.evotec.com                                         
ISIN:        DE0005664809                                           
WKN:         566480                                                 
Indices:     TecDAX                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,  
             München, Stuttgart                                     
End of News    DGAP News-Service  
235331 21.10.2013                                                      
Press spacebar to pause and continue. Press esc to stop.